A Strategic Partnership to Accelerate Access to Clinical Trials Across Europe and Beyond
- FutureMeds
- 2 days ago
- 3 min read
FutureMeds partners with Phoenix Equity Partners to scale what works and deliver more for patients and clients
FutureMeds was founded by Radoslaw Janiak, Marcin Gondek and Paul Chambers on the belief that better research starts at the site level, with experienced teams, trusted relationships, and an unwavering commitment to delivering for patients, Sponsors, and CROs alike.
Thanks to the trust of our clients, patients, and teams, the organisation that began with one dedicated site now spans seven European countries and offers decentralised trial solutions continent-wide.
And today, we’re excited to share the next step in our journey: Phoenix Equity Partners, a leading UK private equity firm with a track record of scaling founder-led businesses, has become a strategic shareholder in FutureMeds, investing to support the next phase of our growth journey.
This long-term partnership will support our mission to make clinical research more accessible across Europe and beyond.
"Our success to date has been driven by the exceptional people across FutureMeds who bring deep commitment, clinical expertise and a shared culture focused on excellence. We are proud of what we have built together and believe Phoenix is the right partner to support us in the next phase of our journey.”
— Dr Radoslaw Janiak, Co-Founder & CEO
To help lay the foundations for a partnership grounded in strategic alignment and long-term ambition, FutureMeds was advised by Fairmount Partners, a global investment bank with deep expertise in pharma services. Fairmount’s experience spans more than 190 projects in the sector, including 11 focused specifically on clinical research sites and patient recruitment.
Backing a Shared Vision
Phoenix focuses on partnering with founder-led businesses in high-growth niches where it brings deep sector expertise. With Phoenix’ increased focus on building businesses for long-term sustainable growth,
Over several years, Phoenix has built a strong relationship with our leadership team and this investment reflects both confidence in our operational model and conviction in the opportunity ahead.
“We have known the founders, Radek, Marcin and Paul before and have been consistently impressed by the vision, dedication and quality of the team they have built.”
— Kevin Keck, Managing Partner, Phoenix Equity Partners
“Our investment reflects Phoenix’s continued commitment to partnering with founder-led businesses in sectors we understand well and believe in deeply. We’re greatly looking forward to the journey ahead.”
— Barry Robinson, Partner, Phoenix Equity Partners
Increased Value for Our Clients and Partners
The relationship with Phoenix allows us to scale what works and deepen our capabilities without changing what makes us unique.
With additional resources and strategic support, FutureMeds can
Expand our site footprint
Recruit more patients across diverse populations
Build therapeutic expertise in new and complex areas
Accelerate delivery through hybrid and decentralised trial solutions
Driving site and patient-focused technology/AI advancements
"We have grown FutureMeds into the largest network in Europe, but we are still just scratching the surface of what is possible. The opportunity ahead to expand our reach, broaden our capabilities and serve even more patients and sponsors is enormous. We see our partnership with Phoenix as an important step in unlocking the next phase of scale and ambition."
— Paul Chambers, Co-Founder & Chair
More Opportunities for Our People
“This partnership also gives us the platform to accelerate innovation where it matters most, at the site and patient level. With Phoenix’s support, we’ll continue investing in technology that simplifies trial delivery, improves patient access, and enables our sites to tackle complexity with greater speed, insight, and consistency.”
— Marcin Gondek, Co-Founder & CFO
Our people have been the driving force behind FutureMeds’ growth. Building on our culture and values with Phoenix backing we will be able to invest more in our teams, creating further opportunities for training, development, and collaboration across our growing network to increase our teams impact on research.
Looking Ahead
FutureMeds will continue to operate under the leadership of its founding team, with the same mission and values that have driven our growth to date. Phoenix joins as a strategic shareholder, bringing additional resources and expertise to help us scale with precision, strengthen our infrastructure, and deepen our capabilities.
About Phoenix
Phoenix Equity Partners is a UK-based private equity group dedicated to helping ambitious businesses grow with purpose. For over two decades, Phoenix has partnered with founder-led and entrepreneurial teams across a range of sectors, providing capital, strategic guidance, and operational support to scale sustainably.
Phoenix focuses on long-term value creation. Its approach centres on working closely with management teams to build resilient, high-growth businesses that are equipped to lead in their industries for years to come.
The group has a strong track record of backing businesses with clear purpose, robust models, and talented leadership, supporting everything from geographic expansion to digital transformation, talent development, and internationalisation.
At its core, Phoenix is about partnership helping great businesses do more of what makes them great.